Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Capital Expenditures (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Capital Expenditures data on record, last reported at $458000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 117.38% year-over-year to $458000.0; the TTM value through Dec 2025 reached $5.8 million, up 3101.11%, while the annual FY2025 figure was $5.8 million, 3101.11% up from the prior year.
  • Capital Expenditures reached $458000.0 in Q4 2025 per CRNX's latest filing, down from $5.2 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $5.2 million in Q3 2025 and bottomed at -$2.6 million in Q4 2024.
  • Average Capital Expenditures over 5 years is $430000.0, with a median of $205500.0 recorded in 2023.
  • The widest YoY moves for Capital Expenditures: up 950.0% in 2024, down 692.13% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at -$288000.0 in 2021, then surged by 654.17% to $1.6 million in 2022, then tumbled by 72.12% to $445000.0 in 2023, then plummeted by 692.13% to -$2.6 million in 2024, then skyrocketed by 117.38% to $458000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $458000.0 in Q4 2025, $5.2 million in Q3 2025, and -$177000.0 in Q2 2025.